Patients with chronic lymphocytic leukaemia (CLL) typically receive first-line treatment with fludarabine, cyclophosphamide and rituximab (FCR), although other agents have shown promising efficacy over the past decade. These treatments include the combination of the BTK inhibitor ibrutinib and the BCL2 antagonist venetoclax. Now, results from the phase III FLAIR trial demonstrate the superiority of this combination when treatment duration is determined through monitoring of measurable residual disease (MRD).

中文翻译：

---

MRD 引导治疗 CLL 的益处

慢性淋巴细胞白血病 (CLL) 患者通常接受氟达拉滨、环磷酰胺和利妥昔单抗 (FCR) 一线治疗，尽管其他药物在过去十年中已显示出有希望的疗效。这些治疗包括 BTK 抑制剂依鲁替尼和 BCL2 拮抗剂维奈托克的组合。现在，III 期 FLAIR 试验的结果证明，当通过监测可测量残留病灶 (MRD) 来确定治疗持续时间时，该组合的优越性。